Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00GlobeNewswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngGlobeNewswire2019-05-07 09:01:222019-05-07 14:06:31Waylivra Approved In EU For Treating FCS